Stereotaxis (STXS) 10-Q 9 May 14 2014 Q1 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	3 Months Ended
	Mar. 31, 2014	Apr. 15, 2014
Document And Entity Information [Abstract]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	31-Mar-14	'
Document Fiscal Period Focus	'Q1	'
Document Fiscal Year Focus	'2014	'
Entity Registrant Name	'Stereotaxis, Inc.	'
Entity Central Index Key	'0001289340	'
Current Fiscal Year End Date	'--12-31	'
Trading Symbol	'stxs	'
Entity Filer Category	'Smaller Reporting Company	'
Entity Common Stock, Shares Outstanding	'	19,435,325

Balance_Sheets

Balance Sheets (USD $)	Mar. 31, 2014	Dec. 31, 2013
Current assets:	'	'
Cash and cash equivalents	$11,301,844	$13,775,130
Accounts receivable, net of allowance of $377,452 and $383,077 in 2014 and 2013, respectively	8,347,212	7,558,152
Inventories	5,573,124	4,879,039
Prepaid expenses and other current assets	1,929,076	1,945,206
Total current assets	27,151,256	28,157,527
Property and equipment, net	1,047,926	1,184,589
Intangible assets, net	1,604,528	1,679,486
Long-term receivables	'	20,431
Other assets	34,425	34,363
Total assets	29,838,135	31,076,396
Current liabilities:	'	'
Short-term debt and current maturities of long-term debt	'	49,733
Accounts payable	3,155,036	3,512,339
Accrued liabilities	7,804,406	7,079,381
Deferred revenue	8,814,091	7,519,754
Warrants and debt conversion features	6,720,765	5,644,626
Total current liabilities	26,494,298	23,805,833
Long-term debt, less current maturities	18,492,619	18,481,478
Long-term deferred revenue	441,583	491,080
Stockholders' deficit:	'	'
Preferred stock, par value $0.001; 10,000,000 shares authorized, none outstanding at 2014 and 2013	'	'
Common stock, par value $0.001; 300,000,000 shares authorized, 19,407,340 and 19,311,390 shares issued at 2014 and 2013, respectively	19,407	19,311
Additional paid in capital	442,139,537	441,888,155
Treasury stock, 4,015 shares at 2014 and 2013	-205,999	-205,999
Accumulated deficit	-457,543,310	-453,403,462
Total stockholders' deficit	-15,590,365	-11,701,995
Total liabilities and stockholders' deficit	$29,838,135	$31,076,396

Balance_Sheets_Parenthetical

Balance Sheets (Parenthetical) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Balance Sheets [Abstract]	'	'
Accounts receivable, allowance	$377,452	$383,077
Preferred stock, par value	$0.00	$0.00
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares outstanding	0	0
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	300,000,000	300,000,000
Common stock, shares issued	19,407,340	19,311,390
Treasury stock, shares	4,015	4,015

Statements_Of_Operations

Statements Of Operations (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Revenue:	'	'
Systems	$1,334,854	$2,228,077
Disposables, service and accessories	7,019,816	6,180,127
Total revenue	8,354,670	8,408,204
Cost of revenue:	'	'
Systems	559,428	1,191,352
Disposables, service and accessories	1,059,658	1,001,293
Total cost of revenue	1,619,086	2,192,645
Gross margin	6,735,584	6,215,559
Operating expenses:	'	'
Research and development	1,503,446	1,529,207
Sales and marketing	3,631,264	4,856,014
General and administrative	3,829,866	3,423,741
Total operating expenses	8,964,576	9,808,962
Operating loss	-2,228,992	-3,593,403
Other income (expense)	-1,076,139	606,102
Interest income	2,233	1,412
Interest expense	-836,950	-1,934,258
Net loss	($4,139,848)	($4,920,147)
Net loss per common share:	'	'
Basic	($0.21)	($0.61)
Diluted	($0.21)	($0.61)
Weighted average shares used in computing net loss per common share:	'	'
Basic	19,403,325	8,015,226
Diluted	19,403,325	8,015,226

Statements_Of_Cash_Flows

Statements Of Cash Flows (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Cash flows from operating activities	'	'
Net loss	($4,139,848)	($4,920,147)
Adjustments to reconcile net loss to cash used in operating activities:	'	'
Depreciation	136,663	263,170
Amortization of intangible assets	74,958	74,958
Amortization of deferred finance costs and debt discount	70,122	860,890
Share-based compensation	307,992	598,827
Gain on debt conversion	'	-2,095
Adjustment of warrants and convertible debt features	1,076,139	-604,007
Interest due from issuance of stock	'	204,547
Changes in operating assets and liabilities:	'	'
Accounts receivable	-789,933	1,709,291
Other receivables	21,305	54,064
Inventories	-694,085	-389,646
Prepaid expenses and other current assets	-53,993	-179,277
Other assets	-62	-1,170
Accounts payable	-357,303	1,181,230
Accrued liabilities	725,025	-323,555
Deferred revenue	1,244,840	323,115
Net cash used in operating activities	-2,378,180	-1,149,805
Cash flows from investing activities	'	'
Purchase of equipment	'	'
Net cash used in investing activities	'	'
Cash flows from financing activities	'	'
Payments of term note	'	-1,000,000
Proceeds from revolving line of credit	'	11,235,938
Payments of revolving line of credit	'	-9,694,979
Proceeds from Healthcare Royalty Partners debt	'	2,500,000
Payments of Healthcare Royalty Partners debt	-38,592	-108,742
Payments for issuance of stock and warrants	-56,514	'
Net cash provided (used) by financing activities	-95,106	2,932,217
Net increase (decrease) in cash and cash equivalents	-2,473,286	1,782,412
Cash and cash equivalents at beginning of period	13,775,130	7,777,718
Cash and cash equivalents at end of period	$11,301,844	$9,560,130

Description_Of_Business

Description Of Business	3 Months Ended
	Mar. 31, 2014
Description Of Business [Abstract]	'
Description Of Business	'
	1. Description of Business
	Stereotaxis designs, manufactures and markets the Epoch Solution, which is an advanced remote robotic navigation system for use in a hospital’s interventional surgical suite, or “interventional lab”, that we believe revolutionizes the treatment of arrhythmias and coronary artery disease by enabling enhanced safety, efficiency and efficacy for catheter-based, or interventional, procedures.  The Epoch Solution is comprised of the Niobe ES Robotic Magnetic Navigation System (“Niobe ES system”), Odyssey Information Management Solution (“Odyssey Solution”), and the Vdrive Robotic Navigation System (“Vdrive system”).
	The Niobe ES system is the latest generation of the Niobe Robotic Magnetic Navigation System (“Niobe system”), which is designed to enable physicians to complete more complex interventional procedures by providing image guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. This is achieved using externally applied magnetic fields that govern the motion of the working tip of the catheter or guidewire, resulting in improved navigation, efficient procedures and reduced x-ray exposure.
	In addition to the Niobe system and its components, Stereotaxis also has developed the Odyssey Solution, which consolidates all lab information enabling doctors to focus on the patient for optimal procedure efficiency. The system also features a remote viewing and recording capability called the Odyssey Cinema solution, which is an innovative solution delivering synchronized content for optimized workflow, advanced care and improved productivity. This tool includes an archiving capability that allows clinicians to store and replay entire procedures or segments of procedures. This information can be accessed from locations throughout the hospital local area network and over the global Odyssey Network providing physicians with a tool for clinical collaboration, remote consultation and training.
	Our Vdrive system provides navigation and stability for diagnostic and therapeutic devices designed to improve interventional procedures. The Vdrive system complements the Niobe ES system control of therapeutic catheters for fully remote procedures and enables single-operator workflow and is sold as two options, the Vdrive system and the Vdrive Duo system. In addition to the Vdrive system and the Vdrive Duo system, we also manufacture and market various disposable components which can be manipulated by these systems.
	We promote the full Epoch Solution in a typical hospital implementation, subject to regulatory approvals or clearances. The full Epoch Solution implementation requires a hospital to agree to an upfront capital payment and recurring payments. The upfront capital payment typically includes equipment and installation charges. The recurring payments typically include disposable costs for each procedure, equipment service costs beyond warranty period, and software licenses. In hospitals where the full Epoch Solution has not been implemented, equipment upgrade or expansion can be implemented upon purchasing of the necessary upgrade or expansion.
	The core components of Stereotaxis systems have received regulatory clearance in the U.S., Europe, Canada and elsewhere.  The V-Sono ICE catheter manipulator has received U.S. clearance, and a 510(k) Premarket Notification has been submitted with the U.S. Food and Drug Administration for the V-Loop circular catheter manipulator.
	Since our inception, we have generated significant losses. As of March 31, 2014 we had incurred cumulative net losses of approximately $457.5 million.  In May 2011, the Company introduced the Niobe ES system and as of March 31, 2014, the Company had an installed base of 108 Niobe ES systems and has received positive feedback from the physicians at these sites. Between 2011 and 2013, the Company implemented a wide ranging plan to rebalance and reduce operating expenses by 15% to 20% on an annual run rate basis. We expect to incur additional losses throughout the remainder of 2014 as we continue the development and commercialization of our products, conduct our research and development activities and advance new products into clinical development from our existing research programs and marketing initiatives. During 2014, we expect operating expenses to be generally consistent with 2013 with additional investment in certain targeted areas.
	We may be required to raise capital or pursue other financing strategies to continue our operations. Until we can generate significant cash flow from our operations, we expect to continue to fund our operations with cash resources primarily generated from the proceeds of our past and future public offerings, private sales of our equity securities and working capital and equipment financing loans. In the future, we may finance cash needs through the sale of other equity securities or non-core assets, strategic collaboration agreements, debt financings or through distribution rights. We cannot accurately predict the timing and amount of our utilization of capital, which will depend on a number of factors outside of our control.
	Our existing cash, cash equivalents and borrowing facilities may not be sufficient to fund our operating expenses and capital equipment requirements through the next 12 months, which would require us to obtain additional financing before that time. We cannot assure that additional financing will be available on a timely basis on terms acceptable to us or at all, or that such financing will not be dilutive to our stockholders. If adequate funds are not available to us, we could be required to delay development or commercialization of new products, to license to third parties the rights to commercialize products or technologies that we would otherwise seek to commercialize ourselves or to reduce the sales, marketing, customer support or other resources devoted to our products, any of which could have a material adverse effect on our business, financial condition and results of operations. In addition, we could be required to cease operations.

Summary_Of_Significant_Account

Summary Of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2014
Summary Of Significant Accounting Policies [Abstract]	'
Summary Of Significant Accounting Policies	'
	2. Summary of Significant Accounting Policies
	Basis of Presentation
	The accompanying unaudited financial statements of Stereotaxis, Inc. have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q. Accordingly, they do not include all the disclosures required by U.S. generally accepted accounting principles for complete financial statements. In the opinion of management, they include all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the results for the interim periods presented. Operating results for the three month period ended March 31, 2014 are not necessarily indicative of the results that may be expected for the year ended December 31, 2014 or for future operating periods.
	These interim financial statements and the related notes should be read in conjunction with the annual financial statements and notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2013 as filed with the Securities and Exchange Commission (SEC) on March 27, 2014.
	As described in Note 10, on July 10, 2012, the Company effected a one-for-ten reverse stock split of the Company’s common stock. All information set forth in the financial statements and related notes gives effect to such reverse stock split.
	Financial Instruments
	The Company measures certain financial assets and liabilities at fair value on a recurring basis, including warrants and debt conversion features. General accounting principles for fair value measurement established a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets and liabilities (“Level 1”) and the lowest priority to unobservable inputs (“Level 3”). See Note 11 for additional details.
	The following methods and assumptions were used by the Company in estimating its fair value disclosures for other financial instruments as of March 31, 2014 and December 31, 2013.
	Cash equivalents, accounts receivable, and accounts payable have carrying values which approximate fair value due to the short maturity or the financial nature of these instruments.
	Long and short-term debt fair value estimates are based on estimated borrowing rates to discount the cash flows to their present value. See Note 9 for disclosure of the fair value of debt.
	Revenue and Costs of Revenue
	The Company accounts for revenue using Accounting Standards Codification Topic 605-25, Multiple-Element Arrangements (“ASC 605-25”).
	ASC 605-25 permits management to estimate the selling price of undelivered components of a bundled sale for which it is unable to establish vendor-specific objective evidence (“VSOE”) or third-party evidence (“TPE”). This requires management to record revenue for certain elements of a transaction even though it might not have delivered other elements of the transaction, for which it was unable to meet the requirements for establishing VSOE or TPE. The Company believes that the guidance significantly improves the reporting of these types of transactions to more closely reflect the underlying economic circumstances. This guidance also prohibits the use of the residual method for allocating revenue to the various elements of a transaction and requires that the revenue be allocated proportionally based on the relative estimated selling prices.
	Under our revenue recognition policy, a portion of revenue for Niobe systems, Vdrive systems and certain Odyssey systems is recognized upon delivery, provided that title has passed, there are no uncertainties regarding acceptance, persuasive evidence of an arrangement exists, the sales price is fixed and determinable, and collection of the related receivable is reasonably assured. Revenue is recognized for other types of Odyssey systems upon completion of installation, since there are no qualified third party installers. When installation is the responsibility of the customer, revenue from system sales is recognized upon shipment since these arrangements do not include an installation element or right of return privileges. The Company does not recognize revenue in situations in which inventory remains at a Stereotaxis warehouse or in situations in which title and risk of loss have not transferred to the customer. Amounts collected prior to satisfying the above revenue recognition criteria are reflected as deferred revenue. Revenue from services and license fees, whether sold individually or as a separate unit of accounting in a multiple-deliverable arrangement, is deferred and amortized over the service or license fee period, which is typically one year. Revenue from services is derived primarily from the sale of annual product maintenance plans. We recognize revenue from disposable device sales or accessories upon shipment and establish an appropriate reserve for returns. The return reserve, which is applicable only to disposable devices, is estimated based on historical experience which is periodically reviewed and updated as necessary. In the past, changes in estimate have had only a de minimis effect on revenue recognized in the period. We believe that the estimate is not likely to change significantly in the future.
	Costs of systems revenue include direct product costs, installation labor and other costs, estimated warranty costs, and initial training and product maintenance costs. These costs are recorded at the time of sale. Costs of disposable revenue include direct product costs and estimated warranty costs and are recorded at the time of sale. Cost of revenue from services and license fees are recorded when incurred.
	Share-Based Compensation
	The Company accounts for its grants of stock options, stock appreciation rights, restricted shares, and restricted stock units and for its employee stock purchase plan in accordance with the provisions of general accounting principles for share-based payments. These accounting principles require the determination of the fair value of the share-based compensation at the grant date and the recognition of the related expense over the period in which the share-based compensation vests.
	The Company utilizes the Black-Scholes valuation model to determine the fair value of stock options and stock appreciation rights at the date of grant. The resulting compensation expense is recognized over the requisite service period, which is generally four years. Compensation expense is recognized only for those awards expected to vest, with forfeitures estimated based on the Company’s historical experience and future expectations. Restricted shares granted to employees are valued at the fair market value at the date of grant. The Company amortizes the fair market value to expense over the service period. If the shares are subject to performance objectives, the resulting compensation expense is amortized over the anticipated vesting period and is subject to adjustment based on the actual achievement of objectives.
	Net Loss per Common Share (“EPS”)
	Basic and diluted net loss per common share (“EPS”) is computed by dividing the net loss for the period by the weighted average number of common shares outstanding during the period.
	The following table sets forth the computation of basic and diluted EPS:
		Three months ended March 31,
		2014		2013
	Numerator:
	Numerator for basic EPS	$	-4,139,848	$	-4,920,147
	Effect of dilutive securities:
	Subordinated convertible debentures		—		—
	Numerator for diluted EPS	$	-4,139,848	$	-4,920,147
	Denominator:
	Denominator for basic EPS—weighted average shares		19,403,325		8,015,226
	Effect of dilutive securities:
	Subordinated convertible debentures		—		—
	Denominator for diluted EPS		19,403,325		8,015,226
	Basic EPS	$	-0.21	$	-0.61
	Diluted EPS	$	-0.21	$	-0.61
	In addition, the Company did not include any portion of unearned restricted shares, outstanding options, stock appreciation rights or warrants in the calculation of diluted loss per common share because all such securities are anti-dilutive for all periods presented. The application of the two-class method of computing earnings per share under general accounting principles for participating securities is not applicable during these periods because the Company’s unearned restricted shares do not contractually participate in its losses.
	As of March  31, 2014, the Company had 516,248 shares of common stock issuable upon the exercise of outstanding options and stock appreciation rights at a weighted average exercise price of $19.57 per share and 2,863,074 shares of common stock issuable upon the exercise of outstanding warrants at a weighted average exercise price of $13.25 per share. The Company had a weighted average of 89 unearned restricted shares outstanding for the period ended March 31, 2014.
	Recently Issued Accounting Pronouncements
	In February 2013, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update (“ASU” or “Update”) 2013-02, “Comprehensive Income: Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income” which adds new disclosure requirements for items reclassified out of accumulated other comprehensive income (“AOCI”). The update requires that the Company present either in a single note or parenthetically on the face of the financial statements, the effect of significant amounts reclassified from each component of AOCI based on its source and the income statement line items affected by the reclassification. The guidance is effective for interim and annual reporting periods beginning on or after December 15, 2012. As the Company has no items of other comprehensive income, the Company is not required to report accumulated other comprehensive income.

Inventory

Inventory	3 Months Ended
	Mar. 31, 2014
Inventory [Abstract]	'
Inventory	'
	3. Inventory
	Inventory consists of the following:
		31-Mar-14	31-Dec-13
	Raw materials	$          2,997,410	$         3,141,111
	Work in process	190,296	364,779
	Finished goods	2,424,541	1,453,362
	Reserve for obsolescence	-39,123	-80,213
	Total inventory	$          5,573,124	$         4,879,039

Prepaid_Expenses_And_Other_Cur

Prepaid Expenses And Other Current Assets	3 Months Ended
	Mar. 31, 2014
Prepaid Expenses And Other Current Assets [Abstract]	'
Prepaid Expenses And Other Current Assets	'
	4. Prepaid Expenses and Other Current Assets
	Prepaid expenses and other current assets consist of the following:
		31-Mar-14	31-Dec-13
	Prepaid expenses	$        689,724	$       591,305
	Deferred cost of revenue	86,267	72,699
	Deferred financing costs	552,826	622,949
	Deposits	600,259	658,253
	Total prepaid expenses and other current assets	$     1,929,076	$    1,945,206
	Deferred cost of revenue represents the cost of systems for which title has transferred from the Company but for which revenue has not been recognized.

Property_And_Equipment

Property And Equipment	3 Months Ended
	Mar. 31, 2014
Property And Equipment [Abstract]	'
Property And Equipment	'
	5. Property and Equipment
	Property and equipment consist of the following:
		March 31,	December 31,
		2014	2013
	Equipment	$          8,143,000	$    8,143,000
	Equipment held for lease	303,412	303,412
	Leasehold improvements	2,328,381	2,328,381
		10,774,793	10,774,793
	Less: Accumulated depreciation	-9,726,867	-9,590,204
	Net property and equipment	$          1,047,926	$    1,184,589

Intangible_Assets

Intangible Assets	3 Months Ended
	Mar. 31, 2014
Intangible Assets [Abstract]	'
Intangible Assets	'
	6. Intangible Assets
	As of March 31, 2014, the Company had total intangible assets, including those described above, of $3,665,000. Accumulated amortization at March  31, 2014,  was $2,060,472.

Accrued_Liabilities

Accrued Liabilities	3 Months Ended
	Mar. 31, 2014
Accrued Liabilities [Abstract]	'
Accrued Liabilities	'
	7. Accrued Liabilities
	Accrued liabilities consist of the following:
		March 31,	December 31,
		2014	2013
	Accrued salaries, bonus, and benefits	$     3,811,420	$    3,565,385
	Accrued rent	1,490,004	1,499,942
	Accrued warranties	449,718	501,212
	Accrued interest	496,405	498,058
	Accrued taxes	293,267	360,475
	Other	1,263,592	654,309
	Total accrued liabilities	$     7,804,406	$    7,079,381
	Our primary company facilities are located in St. Louis, Missouri where we currently lease approximately 52,000 square feet of office and 12,000 square feet of demonstration and assembly space. In the third quarter of 2013, the Company modified the existing lease agreement to terminate approximately 13,000 square feet of unimproved space. The costs associated with the termination were $515,138 and were accrued as a rent liability as of September 30, 2013. As of March 31, 2014, the remaining accrued costs associated with the termination were $473,114.

Deferred_Revenue

Deferred Revenue	3 Months Ended
	Mar. 31, 2014
Deferred Revenue [Abstract]	'
Deferred Revenue	'
	8. Deferred Revenue
	Deferred revenue consists of the following:
		March 31,	December 31,
		2014	2013
	Product shipped, revenue deferred	$      1,265,537	$      1,368,007
	Customer deposits	1,101,638	421,544
	Deferred service and license fees	6,888,499	6,221,283
		9,255,674	8,010,834
	Less: Long-term deferred revenue	-441,583	-491,080
	Total current deferred revenue	$      8,814,091	$      7,519,754

LongTerm_Debt_And_Credit_Facil

Long-Term Debt And Credit Facilities	3 Months Ended
	Mar. 31, 2014
Long-Term Debt And Credit Facilities [Abstract]	'
Long-Term Debt And Credit Facilities	'
	9. Long-Term Debt and Credit Facilities
	Debt outstanding consists of the following:
		31-Mar-14		31-Dec-13
		Carrying	Estimated	Carrying	Estimated
		Amount	Fair Value	Amount	Fair Value
	Healthcare Royalty Partners debt	18,492,619	18,492,619	18,531,211	18,531,211
	Total debt	18,492,619	18,492,619	18,531,211	18,531,211
	Less current maturities	—	—	-49,733	-49,733
	Total long term debt	$   18,492,619	$    18,492,619	$       18,481,478	$       18,481,478
	In accordance with general accounting principles for fair value measurement, the Company’s debt and credit facilities were measured at fair value as of March 31, 2014 and December 31, 2013.  Long-term debt fair value estimates are based on estimated borrowing rates to discount the cash flows to their present value (Level 3).
	Revolving line of credit
	On March 29, 2013, the Company amended its agreement with its primary lender, Silicon Valley Bank, to extend the maturity date of the $13 million working capital line of credit from March 31, 2013 to June 30, 2013. The Company also received from stockholders, who at the time were affiliates of two current and former members of our board of directors (the “Lenders”) and were considered to be related parties, an extension of their commitment to provide $3 million in loan guarantees until June 30, 2013.  As a result of this extension, the Company issued the Lenders warrants to purchase 113,636 shares of common stock at $1.98 per share. Under the facility the Company was required to maintain a minimum “tangible net worth” and liquidity ratio as defined in the agreement.  Interest on the facility accrued at the rate of prime plus 0.5% subject to a floor of 6% for the amount under guarantee and prime plus 1.75% subject to a floor of 7% for the remaining amounts.
	On June 28, 2013, the Company amended its agreement with its primary lender. The amendment extended the maturity date of the working capital line of credit from June 30, 2013 to July 31, 2013, and decreased the amount of available advances from $13 million to $6 million.  In addition, the primary lender waived the testing of the tangible net worth and liquidity ratio financial covenants under the Amended Loan Agreement for the period ended June 30, 2013. The Company and the Lenders also agreed to extend until July 31, 2013 the $3 million guarantee.  As a result of this extension, the Company issued the Lenders warrants to purchase 48,387 shares of common stock at $1.55 per share.
	On July 31, 2013, the Company amended its agreement with its primary lender. The amendment extended the maturity date of the working capital line of credit from July 31, 2013 to August 31, 2013.  In addition, the primary lender waived the testing of the liquidity ratio financial covenant under the Amended Loan Agreement for the period ended July 31, 2013. The Company and the Lenders also agreed to extend until August 31, 2013 the $3 million guarantee.  As a result of this extension, the Company issued the Lenders warrants to purchase 14,313 shares of common stock at $5.24 per share.
	On August 30, 2013, the Company amended its agreement with its primary lender. The amendment extended the maturity date of the working capital line of credit from August 31, 2013 to March 31, 2014. In addition, the Company and the primary lender agreed to a reduction in the revolving credit line from $6.0 million to $3.0 million, the elimination of the $3.0 million sublimit guaranteed by the Lenders, and release of the guarantees by the Lenders in favor of the primary lender. The amendment eliminated the prepayment premium for the prepayment of the term loan and modified the financial covenants to (a) eliminate the minimum tangible net worth covenant, (b) substitute in lieu thereof an EBITDA test, requiring the Company to maintain a minimum EBITDA of no less than (no worse than) (i) negative $4.0 million for the trailing three-month period ending September 30, 2013 and (ii) negative $3.0 million for the trailing three-month period ending December 31, 2013, in each case tested quarterly on a trailing three month basis, and (c) revise the liquidity ratio covenant to require the Company to maintain a liquidity ratio of greater than 2:1, excluding certain short term advances from the calculation.
	On March 28, 2014, the Company amended its agreement with its primary lender. The amendment extended the maturity date of the working capital line of credit from March 31, 2014 to March 31, 2015. In addition, the Company and the primary lender agreed to an increase in the revolving credit line from $3.0 million to $10.0 million and modified the financial covenants to (a) eliminate the EBITDA test, (b) substitute in lieu thereof a minimum tangible net worth test, requiring the Company to maintain a minimum tangible net worth of not less than (no worse than) negative $21 million, with such minimum requirement subject to increase under certain circumstances as described in the agreement, and (c) revise the liquidity ratio covenant to require the Company to maintain a liquidity ratio of greater than 1.75:1.00, excluding certain short term advances from the calculation.
	As of March 31, 2014, the Company had no outstanding debt under the revolving line of credit. Draws on the line of credit are made based on the borrowing capacity one week in arrears. As of March 31, 2014 the Company had a borrowing capacity of $6.2 million based on the Company’s collateralized assets. As such, the Company had ability to borrow $6.2 million under the revolving line of credit at March 31, 2014.
	Term note
	Under the 2010 amendment to the loan agreement, the Company entered into a $10 million term loan maturing on December 31, 2013, with $2 million of principal due in 2011 and $4 million of principal due in each of 2012 and 2013. Interest on the term loan accrued at the rate of the primary lender’s prime plus 3.5% until September 2011, at which point it was adjusted to the lender’s prime plus 5.5%. Under this agreement, the Company provided its primary lender with warrants to purchase 11,111 shares of common stock. The warrants are exercisable at $36.00 per share, beginning on December 17, 2010 and expiring on December 17, 2015. The fair value of these warrants of $228,332, calculated using the Black-Scholes method, was deferred and amortized to interest expense ratably over the life of the term loan. The term note was paid in full in September 2013.
	Healthcare Royalty Partners Debt
	In November 2011, the Company entered into a loan agreement with Healthcare Royalty Partners. Under the agreement the Company borrowed from Healthcare Royalty Partners $15 million. The Company was permitted to borrow up to an additional $5 million in the aggregate based on the achievement by the Company of certain milestones related to Niobe system sales in 2012. On August 8, 2012, the Company borrowed an additional $2.5 million based upon achievement of a milestone related to Niobe system sales for the three months ended June 30, 2012. On January 31, 2013, the Company borrowed an additional $2.5 million based upon achievement of a milestone related to Niobe system sales for the twelve months ended December 31, 2012.  The loan will be repaid through, and secured by, royalties payable to the Company under its Development, Alliance and Supply Agreement with Biosense Webster, Inc. The Biosense Agreement relates to the development and distribution of magnetically enabled catheters used with Stereotaxis' Niobe system in cardiac ablation procedures. Under the terms of the Agreement, Healthcare Royalty Partners will be entitled to receive 100% of all royalties due to the Company under the Biosense Agreement until the loan is repaid.  The loan is a full recourse loan, matures on December 31, 2018, and bears interest at an annual rate of 16% payable quarterly with royalties received under the Biosense Agreement. If the payments received by the Company under the Biosense Agreement are insufficient to pay all amounts of interest due on the loan, then such deficiency will increase the outstanding principal amount on the loan. After the loan obligation is repaid, the royalties under the Biosense Agreement will again be paid to the Company. The loan is also secured by certain assets and intellectual property of the Company. The Agreement also contains customary affirmative and negative covenants. The use of payments due to the Company under the Biosense Agreement was approved by our primary lender under the Amended Loan Agreement described above.
	Subordinated Convertible Debentures
	In May 2012, the Company entered into a securities purchase agreement with certain institutional investors whereby the Company agreed to sell an aggregate of approximately $8.5 million in aggregate principal amount of unsecured, subordinated, convertible debentures (the “Debentures”), which became convertible into shares of the Company’s common stock at a conversion price of $3.361 per share (or approximately 2.5 million shares in the aggregate), on July 10, 2012, the date that the Company received shareholder approval for the transaction.  The purchasers of the Debentures also received six-year warrants to purchase an aggregate of approximately 2.5 million shares of the Company’s common stock at an exercise price of $3.361 per share (“Convert Warrants”).  The Debentures bore interest at 8% per year and were to mature on May 7, 2014.  In addition, the Company had the ability to issue shares of its common stock in lieu of cash interest payments under certain circumstances, and following the registration of the shares for resale, the Company issued shares in lieu of cash interest payments.
	The Company recorded the Debentures on the balance sheet net of the debt discount.  The debt discount of $7.6 million is due to warrants issued in conjunction with the Debentures and the debt conversion features.  Upon issuance of the Debentures, the fair value of the warrants and derivative liability were $4.1 million and $3.5 million, respectively.  The debt discount was amortized over the life of the loan using the effective interest method and the warrants and derivative liability were recorded at fair value on each reporting period.  Refer to Note 11 for additional discussion of the fair value of the warrants.
	On August 7, 2013, holders of Convert Warrants exercised all of their Convert Warrants for an aggregate of approximately 2.5 million shares of our common stock, resulting in cash proceeds of approximately $8.5 million. In addition, holders of all of the Debentures exchanged the balance of their unconverted Debentures for an aggregate of approximately 2.7 million shares of the Company’s common stock and additional warrants (the “Exchange Warrants”) to purchase approximately 2.5 million shares, having an exercise price of $3.361 per share. On August 8, 2013, certain former holders of the Debentures exercised Exchange Warrants to purchase an aggregate of 1.4 million shares of common stock in cashless net exercises as provided for in the Exchange Warrants, which resulted in the issuance to such funds of an aggregate of 0.8 million shares of common stock, but no net proceeds to the Company. The Company is relying on the exemption from registration afforded by Section 4(a)(2) of the Securities Act of 1933, as amended, based on representations to the Company made by the warrant holders.

Stockholders_Equity

Stockholders' Equity	3 Months Ended
	Mar. 31, 2014
Stockholders' Equity [Abstract]	'
Stockholders' Equity	'
	10. Stockholders’ Equity
	Listing Transfer to NASDAQ Capital Market
	On August 15, 2013, the NASDAQ Listing Qualifications Panel (the “Panel”) granted approval of the Company’s request to transfer its listing to The NASDAQ Capital Market® from The NASDAQ Global Market®. The Company’s securities began trading on the NASDAQ Capital Market effective August 19, 2013.
	Reverse Stock Split
	On July 10, 2012, the Company filed a Certificate of Amendment to our Amended and Restated Certificate of Incorporation to implement a one-for-ten reverse split of our common stock (the “Reverse Stock Split”). The ratio for the Reverse Stock Split was determined by our Board of Directors pursuant to the approval of the stockholders at the Company’s special meeting of stockholders held on July 10, 2012, authorizing the Board to effect a reverse stock split within a range of one-for-four to one-for-ten shares of the Company’s common stock. The Reverse Stock Split was effective as of July 10, 2012, and the Company’s common stock began trading on the NASDAQ Global Market on a post-split basis on July 11, 2012.
	As a result of the Reverse Stock Split, each ten shares of the Company’s issued and outstanding common stock were automatically combined and converted into one issued and outstanding share of common stock. The Reverse Stock Split affected all issued and outstanding shares of the Company’s common stock, as well as common stock underlying stock options, stock appreciation rights, restricted stock, restricted stock units, warrants and convertible debentures outstanding immediately prior to the effectiveness of the Reverse Stock Split. The Reverse Stock Split reduced the number of shares of the Company’s common stock outstanding from approximately 78 million to 7.8 million at the time of the Reverse Stock Split. In addition, the Amendment increased the number of authorized shares of the Company’s common stock from 100 million to 300 million. The Reverse Stock Split did not alter the par value of common stock, which remained $0.001 per share, or modify any voting rights or other terms of the Company’s common stock. Unless otherwise indicated, all information set forth herein gives effect to such Reverse Stock Split.
	Private Offerings of Common Stock
	In May 2012, the Company entered into a Stock and Warrant Purchase Agreement with certain institutional investors whereby it agreed to sell an aggregate of approximately 2.17 million shares of the Company's common stock (the “PIPE Common Stock”) at a price of $3.361 per share, together with six-year warrants at a price of $1.25 per share to purchase an aggregate of approximately 2.17 million shares of common stock having an exercise price of $3.361 per share (the “PIPE Warrants”). Each purchaser received a PIPE Warrant to purchase one share of common stock for every share of PIPE Common Stock purchased.  Net proceeds from the sale of the securities were approximately $9.1 million, after placement agent fees and other offering expenses.  The Company used the funds to repay $7 million of the revolving credit facility guaranteed by the Lenders and plans to use the balance for working capital and general corporate purposes.
	On August 7, 2013, venture funds affiliated with Sanderling Ventures received an aggregate of 183,478 shares of common stock based upon the cashless exercise of warrants to purchase an aggregate of 262,450 shares of common stock. These warrants were comprised of 75,758 warrants with an exercise price of $1.98 per share, 156,204 warrants with an exercise price of $3.361 per share and 30,488 warrants with an exercise price of $4.10 per share. The warrants were issued by the Company in private placements in 2012 and 2013 in connection with the extension of previously disclosed guarantees.
	On August 13, 2013, venture funds affiliated with Sanderling Ventures exercised PIPE Warrants to purchase an aggregate of 650,619 shares of common stock in a cashless net exercise as provided for in the PIPE Warrants, which resulted in the issuance to such funds of an aggregate of 308,194 shares of common stock. As a result, there were no net proceeds to the Company.
	On August 16, 2013, certain affiliates of Franklin Templeton exercised PIPE Warrants to purchase an aggregate of 650,618 shares of common stock for cash. The Company received an aggregate of $2,186,727 gross proceeds from the sale.
	On August 16, 2013, Alafi Capital Company exercised PIPE Warrants to purchase an aggregate of 261,241 shares of common stock for cash. The Company received an aggregate of $878,031 gross proceeds from the sale.
	On November 27, 2013, the Company announced the results of its previously announced offering of subscription rights to purchase shares of its common stock, par value $0.001 per share. Pursuant to the rights offering, subscription rights to purchase approximately 3.4 million shares of common stock were exercised, resulting in gross proceeds to Stereotaxis of approximately $10.2 million.
	The holders of common stock are entitled one vote for each share held and to receive dividends whenever funds are legally available and when declared by the Board of Directors subject to the prior rights of holders of all classes of stock having priority rights as dividends and the conditions of the Revolving Credit Agreement. No dividends have been declared or paid as of March 31, 2014.
	Stock Award Plans
	The Company has various stock plans that permit the Company to provide incentives to employees and directors of the Company in the form of equity compensation.  In August 2012, the Board of Directors adopted a stock incentive plan (the 2012 Stock Incentive Plan) which was subsequently approved by the Company’s stockholders. This plan replaces the 2002 Stock Incentive Plan which expired on March 25, 2012.  At March 31, 2014, the Board of Directors had 368,925 remaining shares of the Company’s common stock to provide for current and future grants under its various equity plans.
	At March 31, 2014, the total compensation cost related to options, stock appreciation rights and non-vested stock granted to employees under the Company’s stock award plans but not yet recognized was approximately $2.1 million, net of estimated forfeitures of approximately $2.0 million. This cost will be amortized over a period of up to four years over the underlying estimated service periods and will be adjusted for subsequent changes in estimated forfeitures and anticipated vesting periods.
	A summary of the option and stock appreciation rights activity for the three month period ended March 31, 2014 is as follows:
		Number of Options/SARs	Range of Exercise Price	Weighted Average Exercise Price per Share
	Outstanding, December 31, 2013	188,947	$1.69 - $116.40	$
				48.38
	Granted	336,850	$4.04 - $5.19	$
				4.04
	Exercised	-	-	-
	Forfeited	-9,549	$1.69 - $67.70	$
				41.82
	Outstanding, March 31, 2014	516,248	$1.69 - $116.40	$
				19.57
	As of March 31, 2014, there were no restricted shares outstanding. A summary of the restricted share grant activity for the three month period ended March 31, 2014 is as follows:
		Number of Shares	Weighted Average Grant Date Fair Value per Share
	Outstanding, December 31, 2013	6,600	$
			35.20
	Granted	-	-
	Vested	-6,600	$
			35.20
	Forfeited	-	-
	Outstanding, March 31, 2014	-	$
			0.00
	A summary of the restricted stock unit activity for the three month period ended March 31, 2014 is as follows:
		Number of Restricted Shares Units	Weighted Average Grant Date Fair Value per Unit
	Outstanding, December 31, 2013	588,759	$
			2.05
	Granted	328,400	$
			4.05
	Vested	-95,950	$
			2.49
	Forfeited	-712	$
			1.71
	Outstanding, March 31, 2014	820,497	$
			2.80

Fair_Value_Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2014
Fair Value Measurements [Abstract]	'
Fair Value Measurements	'
	11. Fair Value Measurements
	The Company measures certain financial assets and liabilities at fair value on a recurring basis, including cash equivalents and warrants. General accounting principles for fair value measurement established a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets and liabilities (“Level 1”) and the lowest priority to unobservable inputs (“Level 3”). The three levels of the fair value hierarchy are described below:
	Level 1: Values are based on unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.
	Level 2: Values are based on quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, or other model-based valuation techniques for which all significant assumptions are observable in the market.
	Level 3: Values are generated from model-based techniques that use significant assumptions not observable in the market.
	The following table sets forth the Company’s assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy.  As required by the Fair Value Measurements and Disclosures topic of the Accounting Standards Codification, assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement.
		Fair Value Measurement Using
		Total		Quoted Prices in	Significant	Significant
				Active Markets	Other	Unobservable
				for Identical	Observable	Inputs
				Instruments	Inputs	(Level 3)
				(Level 1)	(Level 2)
	Assets at March 31, 2014:
	Cash equivalents	$	8,970,282	8,970,282	—	—
	Total assets at fair value	$	8,970,282	8,970,282	—	—
	Liabilities at March 31, 2014:
	Warrants issued December 29, 2008	$	597	—	—	597
	Warrants issued May 10, 2012		2,316,594	—	—	2,316,594
	Warrants issued August 2013		4,403,574			4,403,574
	Total liabilities at fair value:	$	6,720,765	—	—	6,720,765
	Assets at December 31, 2013:
	Cash equivalents	$	11,995,481	11,995,481	—	—
	Total assets at fair value	$	11,995,481	11,995,481	—	—
	Liabilities at December 31, 2013:
	Warrants issued December 29, 2008	$	16,863	—	—	16,863
	Warrants issued May 10, 2012		1,915,753	—	—	1,915,753
	Warrants issued August 2013		3,712,010	—	—	3,712,010
	Total liabilities at fair value:	$	5,644,626	—	—	5,644,626
	Level 1
	The Company’s financial assets consist of cash equivalents invested in money market funds in the amount of $8,970,282 and $11,995,481 at March 31, 2014 and December 31, 2013, respectively. These assets are classified as Level 1 as described above and total interest income recorded for these investments was insignificant during both the three month periods ended March 31, 2014 and March 31, 2013. There were no transfers in or out of Level 1 during the period ended March 31, 2014.
	Level 2
	The Company does not have any financial assets or liabilities classified as Level 2.
	Level 3
	In conjunction with its December 29, 2008 registered direct offering, the Company issued warrants to purchase 179,241 shares of the Company’s common stock that contained a provision that required a reduction of the exercise price if certain equity events occurred. Under the provisions of general accounting principles for derivatives and hedging activities and determining whether an instrument (or embedded feature) is indexed to an entity’s own stock, such a reset provision does not meet the exemptions for equity classification and as such, the Company accounts for these warrants as derivative instruments. The calculated fair value of the warrants is classified as a liability and is periodically remeasured with any changes in value recognized in “Other income (expense)” in the Statement of Operations. General accounting principles for determining whether an instrument (or embedded feature) is indexed to an entity’s own stock became effective for the Company as of January 1, 2009. Accordingly, the fair value of the warrants as of that date was reclassified from stockholders’ equity into current liabilities.
	In accordance with general accounting principles for fair value measurement, the Company’s warrants in the amount of $597 were measured at fair value on a recurring basis as of March 31, 2014 and were valued using Level 3 valuation inputs. A Black-Scholes model was used to value the Company’s warrants at March 31, 2014 using the following assumptions: 1) dividend yield of 0%; 2) volatility of 88.68%; 3) risk-free interest rate of 0.9%; and 4) expected life of 0.25 of a year.
	In the Company’s May 2012 financing transaction, the Company issued subordinated convertible debentures and warrants. The optional conversion feature of the subordinated convertible debentures was classified as a derivative liability within “Warrants and derivative liabilities” on the Company’s balance sheet. The warrants issued in conjunction with the Debentures and PIPE are also considered a liability. Due to the provisions included in the warrant agreements, the warrants do not meet the exemptions for equity classification and as such, the Company accounts for these warrants as derivative instruments. The warrants and derivative liability are periodically remeasured with any changes in value recognized in “Other income (expense)” in the Statement of Operations.
	Per the terms of the Debentures agreement, the Company had the ability to require each holder to convert up to 50% of the Debentures if the common stock closed above $15.00, or 100% of the Debentures if the common stock closed above $20.00 (in each case, as adjusted for stock splits, recapitalizations and similar events) during a 20 consecutive trading day period and the resale registration statement had been declared effective by the SEC and was available for the issuance of the common stock upon conversion of the Debentures. In the event of any forced conversion by the Company, the minimum amount that the Company could force the holders to convert was $2.5 million of Debentures in the aggregate. This mandatory redemption clause was classified as a derivative asset within “Prepaid and other current assets” on the Company’s balance sheet. The derivative asset was periodically remeasured with any changes in value recognized in “Other income (expense)” in the Statement of Operations.
	Based on the discussion of the Debentures in Note 10, the Debentures along with their derivative liability and asset, and related warrants were extinguished in the third quarter of 2013.
	The initial valuation of Exchange warrants were valued as of August 7, 2013 using the following assumptions: 1) volatility of 111%; 2) risk-free interest rate of 1.46%; and 3) a closing stock price of $8.69.
	The remaining Exchange warrants were revalued as of March 31, 2014 using the following assumptions: 1) volatility of 146.43%; 2) risk-free interest rate of 1.73%; and 3) a closing stock price of $4.25.
	The remaining PIPE warrants were revalued as of March 31, 2014 using the following assumptions: 1) volatility of 154.24%; 2) risk-free interest rate of 1.73%; and 3) a closing stock price of $4.25.
	The significant unobservable input used in the fair value measurement of the Company’s warrants is volatility.  Significant increases (decreases) in the volatility in isolation would result in a significantly higher (lower) liability fair value measurements.
	The following table sets forth a summary of changes in the fair value of the Company’s Level 3 financial asset and liabilities for the three month period ended March 31, 2014:
			Warrants issued December 29, 2008	Warrants issued May 2012	Warrants issued August 2013	Total Liabilities
	Balance at beginning of period		$                16,863	$           1,915,753	$        3,712,010	$     5,644,626
	Settlements		-	-	-	-
	Revaluation		-16,266	400,841	691,564	1,076,139
	Balance at end of period		$                     597	$           2,316,594	$        4,403,574	$     6,720,765
	The Company currently does not have derivative instruments to manage its exposure to currency fluctuations or other business risks. The Company evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. All derivative financial instruments are recognized in the balance sheet at fair value.

Product_Warranty_Provisions

Product Warranty Provisions	3 Months Ended
	Mar. 31, 2014
Product Warranty Provisions [Abstract]	'
Product Warranty Provisions	'
	12. Product Warranty Provisions
	The Company’s standard policy is to warrant all Niobe,  Odyssey, and Vdrive systems against defects in material or workmanship for one year following installation. The Company’s estimate of costs to service the warranty obligations is based on historical experience and current product performance trends. A regular review of warranty obligations is performed to determine the adequacy of the reserve and adjustments are made to the estimated warranty liability as appropriate.
	Accrued warranty, which is included in other accrued liabilities, consists of the following:
		31-Mar-14		31-Dec-13
	Warranty accrual, beginning of the fiscal period	$	501,212	$	653,473
	Accrual adjustment for product warranty		-34,553		84,562
	Payments made		-16,941		-236,823
	Warranty accrual, end of the fiscal period	$	449,718	$	501,212

Commitments_And_Contingencies

Commitments And Contingencies	3 Months Ended
	Mar. 31, 2014
Commitments And Contingencies [Abstract]	'
Commitments And Contingencies	'
	13. Commitments and Contingencies
	The Company at times becomes a party to claims in the ordinary course of business. Management believes that the ultimate resolution of pending or threatened proceedings will not have a material effect on the financial position, results of operations or liquidity of the Company.
	In 2012, the Company entered into a letter of credit to support a commitment in the amount of approximately $0.1 million. This letter of credit is valid through 2015.

Subsequent_Events

Subsequent Events	3 Months Ended
	Mar. 31, 2014
Subsequent Events [Abstract]	'
Subsequent Events	'
	14. Subsequent Events
	None.

Summary_Of_Significant_Account1

Summary Of Significant Accounting Policies (Policy)	3 Months Ended
	Mar. 31, 2014
Summary Of Significant Accounting Policies [Abstract]	'
Basis Of Presentation	'
	Basis of Presentation
	The accompanying unaudited financial statements of Stereotaxis, Inc. have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q. Accordingly, they do not include all the disclosures required by U.S. generally accepted accounting principles for complete financial statements. In the opinion of management, they include all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the results for the interim periods presented. Operating results for the three month period ended March 31, 2014 are not necessarily indicative of the results that may be expected for the year ended December 31, 2014 or for future operating periods.
	These interim financial statements and the related notes should be read in conjunction with the annual financial statements and notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2013 as filed with the Securities and Exchange Commission (SEC) on March 27, 2014.
	As described in Note 10, on July 10, 2012, the Company effected a one-for-ten reverse stock split of the Company’s common stock. All information set forth in the financial statements and related notes gives effect to such reverse stock split.
Financial Instruments	'
	Financial Instruments
	The Company measures certain financial assets and liabilities at fair value on a recurring basis, including warrants and debt conversion features. General accounting principles for fair value measurement established a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets and liabilities (“Level 1”) and the lowest priority to unobservable inputs (“Level 3”). See Note 11 for additional details.
	The following methods and assumptions were used by the Company in estimating its fair value disclosures for other financial instruments as of March 31, 2014 and December 31, 2013.
	Cash equivalents, accounts receivable, and accounts payable have carrying values which approximate fair value due to the short maturity or the financial nature of these instruments.
	Long and short-term debt fair value estimates are based on estimated borrowing rates to discount the cash flows to their present value. See Note 9 for disclosure of the fair value of debt.
Revenue And Costs Of Revenue	'
	Revenue and Costs of Revenue
	The Company accounts for revenue using Accounting Standards Codification Topic 605-25, Multiple-Element Arrangements (“ASC 605-25”).
	ASC 605-25 permits management to estimate the selling price of undelivered components of a bundled sale for which it is unable to establish vendor-specific objective evidence (“VSOE”) or third-party evidence (“TPE”). This requires management to record revenue for certain elements of a transaction even though it might not have delivered other elements of the transaction, for which it was unable to meet the requirements for establishing VSOE or TPE. The Company believes that the guidance significantly improves the reporting of these types of transactions to more closely reflect the underlying economic circumstances. This guidance also prohibits the use of the residual method for allocating revenue to the various elements of a transaction and requires that the revenue be allocated proportionally based on the relative estimated selling prices.
	Under our revenue recognition policy, a portion of revenue for Niobe systems, Vdrive systems and certain Odyssey systems is recognized upon delivery, provided that title has passed, there are no uncertainties regarding acceptance, persuasive evidence of an arrangement exists, the sales price is fixed and determinable, and collection of the related receivable is reasonably assured. Revenue is recognized for other types of Odyssey systems upon completion of installation, since there are no qualified third party installers. When installation is the responsibility of the customer, revenue from system sales is recognized upon shipment since these arrangements do not include an installation element or right of return privileges. The Company does not recognize revenue in situations in which inventory remains at a Stereotaxis warehouse or in situations in which title and risk of loss have not transferred to the customer. Amounts collected prior to satisfying the above revenue recognition criteria are reflected as deferred revenue. Revenue from services and license fees, whether sold individually or as a separate unit of accounting in a multiple-deliverable arrangement, is deferred and amortized over the service or license fee period, which is typically one year. Revenue from services is derived primarily from the sale of annual product maintenance plans. We recognize revenue from disposable device sales or accessories upon shipment and establish an appropriate reserve for returns. The return reserve, which is applicable only to disposable devices, is estimated based on historical experience which is periodically reviewed and updated as necessary. In the past, changes in estimate have had only a de minimis effect on revenue recognized in the period. We believe that the estimate is not likely to change significantly in the future.
	Costs of systems revenue include direct product costs, installation labor and other costs, estimated warranty costs, and initial training and product maintenance costs. These costs are recorded at the time of sale. Costs of disposable revenue include direct product costs and estimated warranty costs and are recorded at the time of sale. Cost of revenue from services and license fees are recorded when incurred.
Share-Based Compensation	'
	Share-Based Compensation
	The Company accounts for its grants of stock options, stock appreciation rights, restricted shares, and restricted stock units and for its employee stock purchase plan in accordance with the provisions of general accounting principles for share-based payments. These accounting principles require the determination of the fair value of the share-based compensation at the grant date and the recognition of the related expense over the period in which the share-based compensation vests.
	The Company utilizes the Black-Scholes valuation model to determine the fair value of stock options and stock appreciation rights at the date of grant. The resulting compensation expense is recognized over the requisite service period, which is generally four years. Compensation expense is recognized only for those awards expected to vest, with forfeitures estimated based on the Company’s historical experience and future expectations. Restricted shares granted to employees are valued at the fair market value at the date of grant. The Company amortizes the fair market value to expense over the service period. If the shares are subject to performance objectives, the resulting compensation expense is amortized over the anticipated vesting period and is subject to adjustment based on the actual achievement of objectives.
Net Loss Per Common Share	'
	Net Loss per Common Share (“EPS”)
	Basic and diluted net loss per common share (“EPS”) is computed by dividing the net loss for the period by the weighted average number of common shares outstanding during the period.
	The following table sets forth the computation of basic and diluted EPS:
		Three months ended March 31,
		2014		2013
	Numerator:
	Numerator for basic EPS	$	-4,139,848	$	-4,920,147
	Effect of dilutive securities:
	Subordinated convertible debentures		—		—
	Numerator for diluted EPS	$	-4,139,848	$	-4,920,147
	Denominator:
	Denominator for basic EPS—weighted average shares		19,403,325		8,015,226
	Effect of dilutive securities:
	Subordinated convertible debentures		—		—
	Denominator for diluted EPS		19,403,325		8,015,226
	Basic EPS	$	-0.21	$	-0.61
	Diluted EPS	$	-0.21	$	-0.61
	In addition, the Company did not include any portion of unearned restricted shares, outstanding options, stock appreciation rights or warrants in the calculation of diluted loss per common share because all such securities are anti-dilutive for all periods presented. The application of the two-class method of computing earnings per share under general accounting principles for participating securities is not applicable during these periods because the Company’s unearned restricted shares do not contractually participate in its losses.
	As of March  31, 2014, the Company had 516,248 shares of common stock issuable upon the exercise of outstanding options and stock appreciation rights at a weighted average exercise price of $19.57 per share and 2,863,074 shares of common stock issuable upon the exercise of outstanding warrants at a weighted average exercise price of $13.25 per share. The Company had a weighted average of 89 unearned restricted shares outstanding for the period ended March 31, 2014.

Recovered_Sheet1

Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2014
Summary Of Significant Accounting Policies [Abstract]	'
Computation Of Basic And Diluted EPS	'
		Three months ended March 31,
		2014		2013
	Numerator:
	Numerator for basic EPS	$	-4,139,848	$	-4,920,147
	Effect of dilutive securities:
	Subordinated convertible debentures		—		—
	Numerator for diluted EPS	$	-4,139,848	$	-4,920,147
	Denominator:
	Denominator for basic EPS—weighted average shares		19,403,325		8,015,226
	Effect of dilutive securities:
	Subordinated convertible debentures		—		—
	Denominator for diluted EPS		19,403,325		8,015,226
	Basic EPS	$	-0.21	$	-0.61
	Diluted EPS	$	-0.21	$	-0.61

Inventory_Tables

Inventory (Tables)	3 Months Ended
	Mar. 31, 2014
Inventory [Abstract]	'
Schedule Of Inventory	'
		31-Mar-14	31-Dec-13
	Raw materials	$          2,997,410	$         3,141,111
	Work in process	190,296	364,779
	Finished goods	2,424,541	1,453,362
	Reserve for obsolescence	-39,123	-80,213
	Total inventory	$          5,573,124	$         4,879,039

Prepaid_Expenses_And_Other_Cur1

Prepaid Expenses And Other Current Assets (Tables)	3 Months Ended
	Mar. 31, 2014
Prepaid Expenses And Other Current Assets [Abstract]	'
Schedule Of Prepaid Expenses And Other Current Assets	'
		31-Mar-14	31-Dec-13
	Prepaid expenses	$        689,724	$       591,305
	Deferred cost of revenue	86,267	72,699
	Deferred financing costs	552,826	622,949
	Deposits	600,259	658,253
	Total prepaid expenses and other current assets	$     1,929,076	$    1,945,206

Property_And_Equipment_Tables

Property And Equipment (Tables)	3 Months Ended
	Mar. 31, 2014
Property And Equipment [Abstract]	'
Schedule Of Property And Equipment	'
		March 31,	December 31,
		2014	2013
	Equipment	$          8,143,000	$    8,143,000
	Equipment held for lease	303,412	303,412
	Leasehold improvements	2,328,381	2,328,381
		10,774,793	10,774,793
	Less: Accumulated depreciation	-9,726,867	-9,590,204
	Net property and equipment	$          1,047,926	$    1,184,589

Accrued_Liabilities_Tables

Accrued Liabilities (Tables)	3 Months Ended
	Mar. 31, 2014
Accrued Liabilities [Abstract]	'
Schedule Of Accrued Liabilities	'
		March 31,	December 31,
		2014	2013
	Accrued salaries, bonus, and benefits	$     3,811,420	$    3,565,385
	Accrued rent	1,490,004	1,499,942
	Accrued warranties	449,718	501,212
	Accrued interest	496,405	498,058
	Accrued taxes	293,267	360,475
	Other	1,263,592	654,309
	Total accrued liabilities	$     7,804,406	$    7,079,381

Deferred_Revenue_Tables

Deferred Revenue (Tables)	3 Months Ended
	Mar. 31, 2014
Deferred Revenue [Abstract]	'
Schedule Of Deferred Revenue	'
		March 31,	December 31,
		2014	2013
	Product shipped, revenue deferred	$      1,265,537	$      1,368,007
	Customer deposits	1,101,638	421,544
	Deferred service and license fees	6,888,499	6,221,283
		9,255,674	8,010,834
	Less: Long-term deferred revenue	-441,583	-491,080
	Total current deferred revenue	$      8,814,091	$      7,519,754

LongTerm_Debt_And_Credit_Facil1

Long-Term Debt And Credit Facilities (Tables)	3 Months Ended
	Mar. 31, 2014
Long-Term Debt And Credit Facilities [Abstract]	'
Schedule Of Long-Term Debt Outstanding	'
		31-Mar-14		31-Dec-13
		Carrying	Estimated	Carrying	Estimated
		Amount	Fair Value	Amount	Fair Value
	Healthcare Royalty Partners debt	18,492,619	18,492,619	18,531,211	18,531,211
	Total debt	18,492,619	18,492,619	18,531,211	18,531,211
	Less current maturities	—	—	-49,733	-49,733
	Total long term debt	$   18,492,619	$    18,492,619	$       18,481,478	$       18,481,478

Stockholders_Equity_Tables

Stockholder's Equity (Tables)	3 Months Ended
	Mar. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Summary Of The Option And Stock Appreciation Rights Activity	'
		Number of Options/SARs	Range of Exercise Price	Weighted Average Exercise Price per Share
	Outstanding, December 31, 2013	188,947	$1.69 - $116.40	$
				48.38
	Granted	336,850	$4.04 - $5.19	$
				4.04
	Exercised	-	-	-
	Forfeited	-9,549	$1.69 - $67.70	$
				41.82
	Outstanding, March 31, 2014	516,248	$1.69 - $116.40	$
				19.57
Restricted Shares [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Summary Of The Restricted Share Grant Activity	'
		Number of Shares	Weighted Average Grant Date Fair Value per Share
	Outstanding, December 31, 2013	6,600	$
			35.20
	Granted	-	-
	Vested	-6,600	$
			35.20
	Forfeited	-	-
	Outstanding, March 31, 2014	-	$
			0.00
Summary Of The Restricted Stock Unit Activity	'
		Number of Restricted Shares Units	Weighted Average Grant Date Fair Value per Unit
	Outstanding, December 31, 2013	588,759	$
			2.05
	Granted	328,400	$
			4.05
	Vested	-95,950	$
			2.49
	Forfeited	-712	$
			1.71
	Outstanding, March 31, 2014	820,497	$
			2.80

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2014
Fair Value Measurements [Abstract]	'
Assets And Liabilities Measure At Fair Value On A Recurring Basis By Level	'
		Fair Value Measurement Using
		Total		Quoted Prices in	Significant	Significant
				Active Markets	Other	Unobservable
				for Identical	Observable	Inputs
				Instruments	Inputs	(Level 3)
				(Level 1)	(Level 2)
	Assets at March 31, 2014:
	Cash equivalents	$	8,970,282	8,970,282	—	—
	Total assets at fair value	$	8,970,282	8,970,282	—	—
	Liabilities at March 31, 2014:
	Warrants issued December 29, 2008	$	597	—	—	597
	Warrants issued May 10, 2012		2,316,594	—	—	2,316,594
	Warrants issued August 2013		4,403,574			4,403,574
	Total liabilities at fair value:	$	6,720,765	—	—	6,720,765
	Assets at December 31, 2013:
	Cash equivalents	$	11,995,481	11,995,481	—	—
	Total assets at fair value	$	11,995,481	11,995,481	—	—
	Liabilities at December 31, 2013:
	Warrants issued December 29, 2008	$	16,863	—	—	16,863
	Warrants issued May 10, 2012		1,915,753	—	—	1,915,753
	Warrants issued August 2013		3,712,010	—	—	3,712,010
	Total liabilities at fair value:	$	5,644,626	—	—	5,644,626
Summary Of Changes In The Fair Value Of The Company's Level 3 Financial Asset And Liabilities	'
			Warrants issued December 29, 2008	Warrants issued May 2012	Warrants issued August 2013	Total Liabilities
	Balance at beginning of period		$                16,863	$           1,915,753	$        3,712,010	$     5,644,626
	Settlements		-	-	-	-
	Revaluation		-16,266	400,841	691,564	1,076,139
	Balance at end of period		$                     597	$           2,316,594	$        4,403,574	$     6,720,765

Product_Warranty_Provisions_Ta

Product Warranty Provisions (Tables)	3 Months Ended
	Mar. 31, 2014
Product Warranty Provisions [Abstract]	'
Schedule Of Accrued Warranty	'
		31-Mar-14		31-Dec-13
	Warranty accrual, beginning of the fiscal period	$	501,212	$	653,473
	Accrual adjustment for product warranty		-34,553		84,562
	Payments made		-16,941		-236,823
	Warranty accrual, end of the fiscal period	$	449,718	$	501,212

Description_Of_Business_Detail

Description Of Business (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013
	item		Scenario, Forecast [Member]	Scenario, Forecast [Member]
			Minimum [Member]	Maximum [Member]
Description Of Business [Line Items]	'	'	'	'
Cumulative losses incurred from inception	($457,543,310)	($453,403,462)	'	'
Installed base	108	'	'	'
Annual plan to rebalance and reduce operating expenses, percentage	'	'	15.00%	20.00%

Summary_Of_Significant_Account2

Summary Of Significant Accounting Policies (Narrative) (Details) (USD $)	0 Months Ended	3 Months Ended
	Jul. 10, 2012	Mar. 31, 2014	Dec. 31, 2013
Summary Of Significant Accounting Policies [Line Items]	'	'	'
Reverse stock split	0.1	'	'
Stock options and stock appreciation rights	'	516,248	188,947
Weighted average exercise price	'	$19.57	$48.38
Common stock issuable upon exercise of outstanding warrants	'	2,863,074	'
Weighted average exercise price of warrants or rights	'	$13.25	'
Share based compensation, requisite service period	'	'4 years	'
Restricted Shares [Member]	'	'	'
Summary Of Significant Accounting Policies [Line Items]	'	'	'
Weighted average unearned restricted shares outstanding	'	89	'

Recovered_Sheet2

Summary of Significant Accounting Policies (Computation of Basic and Diluted EPS) (Details) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Summary Of Significant Accounting Policies [Abstract]	'	'
Numerator for basic EPS	($4,139,848)	($4,920,147)
Subordinated convertible debentures	'	'
Numerator for diluted EPS	($4,139,848)	($4,920,147)
Denominator for basic EPS - weighted average shares	19,403,325	8,015,226
Subordinated convertible debentures	'	'
Denominator for diluted EPS	19,403,325	8,015,226
Basic EPS	($0.21)	($0.61)
Diluted EPS	($0.21)	($0.61)

Inventory_Schedule_Of_Inventor

Inventory (Schedule Of Inventory) (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Inventory [Abstract]	'	'
Raw materials	$2,997,410	$3,141,111
Work in process	190,296	364,779
Finished goods	2,424,541	1,453,362
Reserve for obsolescence	-39,123	-80,213
Total inventory	$5,573,124	$4,879,039

Prepaid_Expenses_And_Other_Cur2

Prepaid Expenses And Other Current Assets (Schedule Of Prepaid Expenses And Other Current Assets) (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Prepaid Expenses And Other Current Assets [Abstract]	'	'
Prepaid expenses	$689,724	$591,305
Deferred cost of revenue	86,267	72,699
Deferred financing costs	552,826	622,949
Deposits	600,259	658,253
Total prepaid expenses and other current assets	$1,929,076	$1,945,206

Property_And_Equipment_Schedul

Property And Equipment (Schedule Of Property And Equipment) (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Property, Plant and Equipment [Line Items]	'	'
Gross property and equipment	$10,774,793	$10,774,793
Less: Accumulated depreciation	-9,726,867	-9,590,204
Net property and equipment	1,047,926	1,184,589
Equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Gross property and equipment	8,143,000	8,143,000
Equipment Held For Lease [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Gross property and equipment	303,412	303,412
Leasehold Improvements [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Gross property and equipment	$2,328,381	$2,328,381

Intangible_Assets_Details

Intangible Assets (Details) (USD $)	Mar. 31, 2014
Intangible Assets [Abstract]	'
Total intangible assets, including those subject to execution of agreement	$3,665,000
Accumulated amortization	$2,060,472

Accrued_Liabilities_Schedule_O

Accrued Liabilities (Schedule Of Accrued Liabilities) (Details) (USD $)	3 Months Ended
	Mar. 31, 2014	Sep. 30, 2013	Dec. 31, 2013	Dec. 31, 2012
	sqft	sqft
Operating Leased Assets [Line Items]	'	'	'	'
Accrued salaries, bonus, and benefits	$3,811,420	'	$3,565,385	'
Accrued rent	1,490,004	'	1,499,942	'
Accrued warranties	449,718	'	501,212	653,473
Accrued interest	496,405	'	498,058	'
Accrued taxes	293,267	'	360,475	'
Other	1,263,592	'	654,309	'
Total accrued liabilities	7,804,406	'	7,079,381	'
Square feet of office leased space	52,000	'	'	'
Square feet of demonstration and assembly leased space	12,000	'	'	'
Square feet of terminated unimproved space leased space	'	13,000	'	'
Lease Termination Costs [Member]	'	'	'	'
Operating Leased Assets [Line Items]	'	'	'	'
Accrued rent	$473,114	515,138	'	'

Deferred_Revenue_Schedule_Of_D

Deferred Revenue (Schedule Of Deferred Revenue) (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Deferred Revenue Arrangement [Line Items]	'	'
Deferred revenue	$9,255,674	$8,010,834
Less: Long-term deferred revenue	-441,583	-491,080
Total current deferred revenue	8,814,091	7,519,754
Product Shipped, Revenue Deferred [Member]	'	'
Deferred Revenue Arrangement [Line Items]	'	'
Deferred revenue	1,265,537	1,368,007
Customer Deposits [Member]	'	'
Deferred Revenue Arrangement [Line Items]	'	'
Deferred revenue	1,101,638	421,544
Deferred Service And License Fees [Member]	'	'
Deferred Revenue Arrangement [Line Items]	'	'
Deferred revenue	$6,888,499	$6,221,283

LongTerm_Debt_And_Credit_Facil2

Long-Term Debt And Credit Facilities (Revolving Line Of Credit) (Narrative) (Details) (USD $)

Mar. 31, 2014

31-May-12

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Dec. 31, 2013

Sep. 30, 2013

Mar. 31, 2014

Mar. 31, 2014

Revolving Line Of Credit [Member]

May 10, 2012 Amendment [Member]

March 2013 Amendment [Member]

March 2013 Amendment [Member]

June 2013 Amendment [Member]

June 2013 Amendment [Member]

July 2013 Amendment [Member]

July 2013 Amendment [Member]

August 2013 Amendment [Member]

August 2013 Amendment [Member]

August 2013 Amendment [Member]

August 2013 Amendment [Member]

March 2014 Amendment [Member]

Revolving Line Of Credit [Member]

Revolving Line Of Credit [Member]

Revolving Line Of Credit [Member]

Revolving Line Of Credit [Member]

Revolving Line Of Credit [Member]

Revolving Line Of Credit [Member]

Revolving Line Of Credit [Member]

Revolving Line Of Credit [Member]

Revolving Line Of Credit [Member]

Revolving Line Of Credit [Member]

Revolving Line Of Credit [Member]

Revolving Line Of Credit [Member]

Guarantees Provided By Lenders [Member]

Guarantees Provided By Lenders [Member]

Guarantees Provided By Lenders [Member]

Guarantees Provided By Lenders [Member]

Debt Instrument [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Maximum borrowing capacity

'

'

'

'

$13,000,000

$3,000,000

$6,000,000

$3,000,000

'

$3,000,000

$3,000,000

'

'

$0

$10,000,000

Debt maturity date

'

'

'

31-Mar-13

30-Jun-13

30-Jun-13

31-Jul-13

31-Jul-13

31-Aug-13

31-Aug-13

31-Mar-14

'

'

'

31-Mar-15

Interest rate added to prime rate

'

'

'

'

1.75%

0.50%

'

'

'

'

'

'

'

'

'

Accrued interest on facility, floor

'

'

'

'

7.00%

6.00%

'

'

'

'

'

'

'

'

'

Earnings before interest and depreciation and amortization revolving credit convenant

'

'

'

'

'

'

'

'

'

'

'

-3,000,000

-4,000,000

'

'

Warrants

2,863,074

'

'

'

113,636

'

48,387

'

14,313

'

'

'

'

'

'

Exercise price of warrants

'

$3.36

'

'

$1.98

'

$1.55

'

$5.24

'

'

'

'

'

'

Tangible net worth requirement

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-21,000,000

Liquidity ratio

'

'

'

'

'

'

'

'

'

'

2

'

'

'

1.75

Line of credit facility, amount outstanding

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

Current borrowing capacity

'

'

6,200,000

'

'

'

'

'

'

'

'

'

'

'

'

Line of credit, current availability

'

'

$6,200,000

'

'

'

'

'

'

'

'

'

'

'

'

LongTerm_Debt_And_Credit_Facil3

Long-Term Debt And Credit Facilities (Remaining Content) (Narrative) (Details) (USD $)

3 Months Ended

0 Months Ended

3 Months Ended

0 Months Ended

1 Months Ended

3 Months Ended

1 Months Ended

3 Months Ended

21 Months Ended

Mar. 31, 2013

Mar. 31, 2014

31-May-12

Aug. 07, 2013

Aug. 08, 2013

Aug. 07, 2013

Mar. 31, 2014

Dec. 31, 2010

Aug. 08, 2013

Jan. 31, 2013

Nov. 30, 2011

Mar. 31, 2014

31-May-12

Aug. 07, 2013

Dec. 31, 2011

Sep. 30, 2011

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Convert Warrants [Member]

Exchange Warrants [Member]

Exchange Warrants [Member]

Term Note [Member]

Term Note [Member]

Healthcare Royalty Partners debt [Member]

Healthcare Royalty Partners debt [Member]

Healthcare Royalty Partners debt [Member]

Healthcare Royalty Partners debt [Member]

Subordinated Convertible Debentures [Member]

Unconverted Debentures [Member]

2010 Amendment To Loan Agreement [Member]

2010 Amendment To Loan Agreement [Member]

Principal Due 2013 [Member]

Principal Due 2012 [Member]

Principal Due 2011 [Member]

item

Term Note [Member]

Term Note [Member]

Term Note [Member]

Term Note [Member]

Term Note [Member]

Lender's Prime Rate [Member]

Lender's Prime Rate [Member]

Debt Instrument [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt maturity date

'

'

'

'

'

'

31-Dec-13

'

'

'

'

31-Dec-18

'

'

'

'

'

'

'

Interest rate added to prime rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5.50%

3.50%

'

'

'

Warrants

'

2,863,074

'

'

'

2,500,000

'

11,111

'

'

'

'

2,500,000

'

'

'

'

'

'

Number of shares issued upon conversion of warrants

'

'

'

'

1,400,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Aggregate number of shares issued upon conversion

'

'

'

2,500,000

800,000

'

'

'

'

'

'

'

'

2,700,000

'

'

'

'

'

Proceeds from the exercise of stock warrants

'

'

'

$8,500,000

$0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise price of warrants

'

'

$3.36

'

'

$3.36

'

$36

'

'

'

'

$3.36

'

'

'

'

'

'

Fair value of warrants issued

'

'

'

'

'

'

'

228,332

'

'

'

'

'

'

'

'

'

'

'

Term loan agreement, face value

'

'

'

'

'

'

'

10,000,000

'

'

'

'

'

'

'

'

'

'

'

Term loan principal amount due

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4,000,000

4,000,000

2,000,000

Amount borrowed

2,500,000

'

'

'

'

'

'

'

'

'

15,000,000

'

'

'

'

'

'

'

'

Additional amount which may be borrowed

'

'

'

'

'

'

'

'

'

'

5,000,000

'

'

'

'

'

'

'

'

Percentage of royalties entitled to

'

'

'

'

'

'

'

'

'

'

100.00%

'

'

'

'

'

'

'

'

Annual interest rate

'

'

'

'

'

'

'

'

'

'

16.00%

'

8.00%

'

'

'

'

'

'

Additional amount borrowed

'

'

'

'

'

'

'

'

2,500,000

2,500,000

'

'

'

'

'

'

'

'

'

Proceeds from Convertible Debt

'

'

'

'

'

'

'

'

'

'

'

'

8,500,000

'

'

'

'

'

'

Conversion price per share

'

'

'

'

'

'

'

'

'

'

'

'

$3.36

'

'

'

'

'

'

Number of convertible shares

'

'

'

'

'

'

'

'

'

'

'

'

2,500,000

'

'

'

'

'

'

Debt discount

'

'

'

'

'

'

'

'

'

'

'

'

7,600,000

'

'

'

'

'

'

Fair value of warrants

'

'

'

'

'

'

'

'

'

'

'

'

4,100,000

'

'

'

'

'

'

Fair value of derivative liability

'

'

'

'

'

'

'

'

'

'

'

'

$3,500,000

'

'

'

'

'

'

LongTerm_Debt_And_Credit_Facil4

Long-Term Debt And Credit Facilities (Schedule Of Long-Term Debt Outstanding) (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Debt Instrument [Line Items]	'	'
Total debt, Carrying Amount	$18,492,619	$18,531,211
Less current maturities, Carrying Amount	'	-49,733
Total long term debt, Carrying Amount	18,492,619	18,481,478
Total debt, Estimated Fair Value	18,492,619	18,531,211
Less current maturities, Estimated Fair Value	'	-49,733
Total long term debt, Estimated Fair Value	18,492,619	18,481,478
Healthcare Royalty Partners debt [Member]	'	'
Debt Instrument [Line Items]	'	'
Total debt, Carrying Amount	18,492,619	18,531,211
Total debt, Estimated Fair Value	$18,492,619	$18,531,211

Stockholders_Equity_Narrative_

Stockholders' Equity (Narrative) (Details) (USD $)

0 Months Ended

1 Months Ended

3 Months Ended

1 Months Ended

0 Months Ended

0 Months Ended

Jul. 10, 2012

31-May-12

Mar. 31, 2014

Dec. 31, 2013

Nov. 27, 2013

Jul. 10, 2012

Jul. 10, 2012

Jul. 10, 2012

Jul. 10, 2012

Aug. 07, 2013

Aug. 07, 2013

Aug. 07, 2013

Aug. 07, 2013

Aug. 13, 2013

Aug. 16, 2013

Aug. 16, 2013

item

Rights [Member]

Pre-Stock Split [Member]

Post-Stock Split [Member]

Minimum [Member]

Maximum [Member]

Warrrant Exercise Price $1.98 [Member]

Warrrant Exercise Price $3.361 [Member]

Warrrant Exercise Price $4.10 [Member]

Sanderling Ventures PIPE Warrants [Member]

Sanderling Ventures PIPE Warrants [Member]

Franklin Templeton PIPE Warrants [Member]

Alafi Capital Company PIPE Warrants [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Reverse stock split

0.1

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Authorized reverse stock split

'

'

'

'

'

'

'

0.25

0.1

'

'

'

'

'

'

'

Common stock outstanding

'

'

'

'

'

78,000,000

7,800,000

'

'

'

'

'

'

'

'

'

Common stock authorized

100,000,000

'

300,000,000

300,000,000

'

'

'

'

'

'

'

'

'

'

'

'

Common stock par value

'

'

$0.00

$0.00

'

'

'

'

'

'

'

'

'

'

'

'

Shares sold in private placement

'

2,170,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share price of shares sold in private placement

'

3.361

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants sold in private placement

'

2,170,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Duration period of warrants

'

'6 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share price of warrants sold in private placement

'

$1.25

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise price of warrants

'

$3.36

'

'

'

'

'

'

'

$1.98

$3.36

$4.10

'

'

'

'

Net proceeds from sale of securities

'

$9,100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Paydown of the guarantees

'

7,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of shares issued upon conversion of warrants

'

'

'

'

'

'

'

'

'

'

'

'

183,478

308,194

'

'

Aggregate number of shares issued upon conversion of subscription rights

'

'

'

'

3,400,000

'

'

'

'

75,758

156,204

30,488

262,450

650,619

650,618

261,241

Proceeds from the exercise of stock warrants

'

'

'

'

10,200,000

'

'

'

'

'

'

'

'

'

2,186,727

878,031

Votes per share

'

'

1

'

'

'

'

'

'

'

'

'

'

'

'

'

Dividends declared

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

Dividends paid

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

Total compensation cost not yet recognized related to options, stock appreciation rights and non-vested stock granted to employees

'

'

2,100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Estimated forfeitures

'

'

$2,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Remaining shares of Company's common stock to provide for current and future grants under its various equity plans

'

'

368,925

'

'

'

'

'

'

'

'

'

'

'

'

'

Total compensation cost not yet recognized related to options, stock appreciation rights and non-vested stock granted to employees, period of amortization, in years

'

'

'4 years

'

'

'

'

'

'

'

'

'

'

'

'

'

Stockholders_Equity_Summary_Of

Stockholders' Equity (Summary Of The Option And Stock Appreciation Rights Activity) (Details) (USD $)	3 Months Ended	12 Months Ended	3 Months Ended
	Mar. 31, 2014	Dec. 31, 2013	Mar. 31, 2014	Mar. 31, 2014	Mar. 31, 2014
		$1.69 - $116.40 [Member]	$4.04 - $5.19 [Member]	$1.69 - $67.70 [Member]	$1.69 - $116.40 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'	'	'	'
Number of Options/SARs, Outstanding, December 31, 2013	188,947	'	'	'	'
Number of Options/SARs, Granted	336,850	'	'	'	'
Number of Options/SARs, Forfeited	-9,549	'	'	'	'
Number of Options/SARs, Outstanding, March 31, 2014	516,248	'	'	'	'
Weighted Average Exercise Price per Share, Outstanding, December 31, 2013	$48.38	'	'	'	'
Weighted Average Exercise Price per Share, Granted	$4.04	'	'	'	'
Weighted Average Exercise Price per Share, Forfeited	$41.82	'	'	'	'
Weighted Average Exercise Price per Share, Outstanding, March 31, 2014	$19.57	'	'	'	'
Range of Exercise Price, Lower limit	'	$1.69	$4.04	$1.69	$1.69
Range of Exercise Price, Upper limit	'	$116.40	$5.19	$67.70	$116.40

Stockholders_Equity_Summary_Of1

Stockholders' Equity (Summary Of The Restricted Share Grant Activity) (Details) (Restricted Shares [Member], USD $)	3 Months Ended
	Mar. 31, 2014
Restricted Shares [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Number of Shares, Outstanding, December 31, 2013	6,600
Number of Shares, Vested	-6,600
Weighted Average Grant Date Fair Value per Share/Unit, Outstanding, December 31, 2013	$35.20
Weighted Average Grant Date Fair Value per Share/Unit, Vested	$35.20
Weighted Average Grant Date Fair Value per Share/Unit, Outstanding, March 31, 2014	$0

Stockholders_Equity_Summary_Of2

Stockholders' Equity (Summary Of The Restricted Stock Unit Activity) (Details) (Restricted Stock Units [Member], USD $)	3 Months Ended
	Mar. 31, 2014
Restricted Stock Units [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Number of Shares, Outstanding, December 31, 2013	588,759
Number of Shares, Granted	328,400
Number of Shares, Vested	-95,950
Number of Shares, Forfeited	-712
Number of Shares, Outstanding, March 31, 2014	820,497
Weighted Average Grant Date Fair Value per Share/Unit, Outstanding, December 31, 2013	$2.05
Weighted Average Grant Date Fair Value per Share/Unit, Granted	$4.05
Weighted Average Grant Date Fair Value per Share/Unit, Vested	$2.49
Weighted Average Grant Date Fair Value per Share/Unit, Forfeited	$1.71
Weighted Average Grant Date Fair Value per Share/Unit, Outstanding, March 31, 2014	$2.80

Fair_Value_Measurements_Narrat

Fair Value Measurements (Narrative) (Details) (USD $)

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Dec. 31, 2013

Dec. 29, 2008

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2014

Aug. 07, 2013

Mar. 31, 2014

Aug. 07, 2013

Mar. 31, 2014

Warrants Issued December 29, 2008 [Member]

Warrants Issued December 29, 2008 [Member]

Common Stock Closes Above $15.00 [Member]

Common Stock Closes Above $20.00 [Member]

Fair Value, Inputs, Level 1 [Member]

Fair Value, Inputs, Level 1 [Member]

Fair Value, Inputs, Level 3 [Member]

Fair Value, Inputs, Level 3 [Member]

Fair Value, Inputs, Level 3 [Member]

Fair Value, Inputs, Level 3 [Member]

Exchange Warrants [Member]

Exchange Warrants [Member]

Exchange Warrants [Member]

PIPE Warrants [Member]

Warrants Issued December 29, 2008 [Member]

Warrants Issued December 29, 2008 [Member]

Black-Scholes Model Used to Value Warrants [Member]

Black-Scholes Model Used to Value Warrants [Member]

Monte-Carlo Simulation Used To Value Derivative Assets And Liabilities [Member]

Black-Scholes Model Used to Value Warrants [Member]

Warrants Issued December 29, 2008 [Member]

Fair Value Measurements [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cash equivalents invested in money market funds

$8,970,282

$11,995,481

'

'

'

'

$8,970,282

$11,995,481

'

'

'

'

'

'

'

'

Issued warrants to purchase shares of common stock

2,863,074

'

'

'

'

'

'

'

179,241

'

'

'

2,500,000

'

'

'

Fair value of warrants issued

'

'

597

16,863

'

'

'

'

'

597

16,863

597

'

'

'

'

Dividend yield

'

'

'

'

'

'

'

'

'

'

'

0.00%

'

'

'

'

Volatility rate

'

'

'

'

'

'

'

'

'

'

'

88.68%

'

146.43%

111.00%

154.24%

Risk-free interest rate

'

'

'

'

'

'

'

'

'

'

'

0.90%

'

1.73%

1.46%

1.73%

Expected life

'

'

'

'

'

'

'

'

'

'

'

'3 months

'

'

'

'

Closing stock price

'

'

'

'

'

'

'

'

'

'

'

'

'

$4.25

$8.69

$4.25

Mandatory conversion percentage per Debentures agreement

'

'

'

'

50.00%

100.00%

'

'

'

'

'

'

'

'

'

'

Share price which determines conversion per Debentures agreement

'

'

'

'

15

20

'

'

'

'

'

'

'

'

'

'

Number of consecutive trading days required at stock price

'

'

'

'

'20 days

'20 days

'

'

'

'

'

'

'

'

'

'

Mandatory conversion minimum per Debentures agreement

'

'

'

'

$2,500,000

$2,500,000

'

'

'

'

'

'

'

'

'

'

Fair_Value_Measurements_Assets

Fair Value Measurements (Assets And Liabilities Measure At Fair Value On A Recurring Basis By Level) (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Cash equivalents	$8,970,282	$11,995,481
Total Assets at Fair Value	8,970,282	11,995,481
Total Liabilities at Fair Value	6,720,765	5,644,626
Warrants Issued December 29, 2008 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Fair value of warrants issued	597	16,863
Warrants Issued May 10, 2012 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Fair value of warrants issued	2,316,594	1,915,753
Warrants Issued August 2013 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Fair value of warrants issued	4,403,574	3,712,010
Fair Value, Inputs, Level 1 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Cash equivalents	8,970,282	11,995,481
Total Assets at Fair Value	8,970,282	11,995,481
Fair Value, Inputs, Level 2 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Cash equivalents	'	'
Total Assets at Fair Value	'	'
Total Liabilities at Fair Value	'	'
Fair Value, Inputs, Level 2 [Member] | Warrants Issued December 29, 2008 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Fair value of warrants issued	'	'
Fair Value, Inputs, Level 2 [Member] | Warrants Issued May 10, 2012 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Fair value of warrants issued	'	'
Fair Value, Inputs, Level 2 [Member] | Warrants Issued August 2013 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Fair value of warrants issued	'	'
Fair Value, Inputs, Level 3 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Total Liabilities at Fair Value	6,720,765	5,644,626
Fair Value, Inputs, Level 3 [Member] | Warrants Issued December 29, 2008 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Fair value of warrants issued	597	16,863
Fair Value, Inputs, Level 3 [Member] | Warrants Issued May 10, 2012 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Fair value of warrants issued	2,316,594	1,915,753
Fair Value, Inputs, Level 3 [Member] | Warrants Issued August 2013 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Fair value of warrants issued	$4,403,574	$3,712,010

Fair_Value_Measurements_Summar

Fair Value Measurements (Summary Of Changes In The Fair Value Of The Company's Level 3 Financial Asset And Liabilities) (Details) (USD $)	3 Months Ended
	Mar. 31, 2014
Fair Value, Assets And Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]	'
Liabilities, Balance at beginning of period	$5,644,626
Liabilities, Settlements	'
Liabilities, Revaluation	1,076,139
Liabilities, Balance at end of period	6,720,765
Warrants Issued December 29, 2008 [Member]	'
Fair Value, Assets And Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]	'
Liabilities, Balance at beginning of period	16,863
Liabilities, Settlements	'
Liabilities, Revaluation	-16,266
Liabilities, Balance at end of period	597
Warrants Issued May 10, 2012 [Member]	'
Fair Value, Assets And Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]	'
Liabilities, Balance at beginning of period	1,915,753
Liabilities, Settlements	'
Liabilities, Revaluation	400,841
Liabilities, Balance at end of period	2,316,594
Warrants Issued August 2013 [Member]	'
Fair Value, Assets And Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]	'
Liabilities, Balance at beginning of period	3,712,010
Liabilities, Settlements	'
Liabilities, Revaluation	691,564
Liabilities, Balance at end of period	$4,403,574

Product_Warranty_Provisions_Sc

Product Warranty Provisions (Schedule Of Accrued Warranty) (Details) (USD $)	3 Months Ended	12 Months Ended
	Mar. 31, 2014	Dec. 31, 2013
Product Warranty Provisions [Abstract]	'	'
Warranty accrual, beginning of the fiscal period	$501,212	$653,473
Accrual adjustment for product warranty	-34,553	84,562
Payments made	-16,941	-236,823
Warranty accrual, end of the fiscal period	$449,718	$501,212
Standard product warranty, coverage term	'1 year	'

Commitments_And_Contingencies_

Commitments And Contingencies (Details) (USD $)	Dec. 31, 2012
In Millions, unless otherwise specified
Commitments And Contingencies [Abstract]	'
Letter of credit	$0.10